ADAP - Adaptimmune provides complete contents of its SITC Abstract for SURPASS Trial

Adaptimmune Therapeutics (ADAP) has announced early release of the abstract from SURPASS Phase 1 trial with ADPA2M4CD8, a SPEAR T-cell therapy by the Society for the Immunotherapy of Cancer ((SITC)) Conference.Ongoing trial is evaluating safety and efficacy of ADP-A2M4CD8. Prior to infusion, subjects received lymphodepletion with fludarabine 30mg for 4 days and cyclophosphamide 600mg for 3 days. As of 16 July, 5 patients were treated with ADP-A2M4 CD8. No dose limiting toxicities or serious adverse events were observed. To date, 1 patient with esophagogastric junction cancer had a partial response ((PR)) and has had progression-free survival >6 months. One patient with head & neck cancer also had a PR. All other patients have had best overall response of stable disease.Translational data and early clinical results indicate that co-expression of the CD8? co-receptor on CD4+ SPEAR T-cells may increase the potency of the product by conferring additional killing activity to the helper T-cell subset.

For further details see:

Adaptimmune provides complete contents of its SITC Abstract for SURPASS Trial